Related Experiment Video
Updated: Apr 5, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators
Malik Hamaidia, Bernard Staumont, Bernard Duysinx
1Department of AgroBioChem, University of Liege, 5030, Gembloux, Belgium. luc.willems@ulg.ac.be.
In the absence of a satisfactory treatment of malignant pleural mesothelioma (MPM), novel therapeutic strategies are urgently needed. Among these, immunotherapy offers a series of advantages such as tumor specificity and good tolerability. Unfortunately, MPM immunotherapy is frequently limited by incomplete cell differentiation or feedback loop regulatory mechanisms. In this review, we describe different components of the innate immune system and discuss strategies to improve MPM immunotherapy by using epigenetic modulators.
In the absence of a satisfactory treatment of malignant pleural mesothelioma (MPM), novel therapeutic strategies are urgently needed. Among these, immunotherapy offers a series of advantages such as tumor specificity and good tolerability. Unfortunately, MPM immunotherapy is frequently limited by incomplete cell differentiation or feedback loop regulatory mechanisms. In this review, we describe different components of the innate immune system and discuss strategies to improve MPM immunotherapy by using epigenetic modulators.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Mitogens and the Cell Cycle
Epigenetic Regulation
X-chromosome...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Abnormal Proliferation

